TTNP article June 13th, 2011-Are Titan Pharma shares still meaningfully under-valued?
"Jason Napodano, CFA of Zacks Investment Research recently initiated coverage of Titan Pharmaceuticals, Inc. (OTCBB: TTNP) with an Outperform rating and $4.50 price target."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.